273 related articles for article (PubMed ID: 26482312)
1. Case-Control Study of Telavancin as an Alternative Treatment for Gram-Positive Bloodstream Infections in Patients with Cancer.
Chaftari AM; Hachem R; Jordan M; Garoge K; Al Hamal Z; El Zakhem A; Viola GM; Granwehr B; Mulanovich V; Gagel A; Reitzel R; Yousif A; Jiang Y; Raad I
Antimicrob Agents Chemother; 2016 Jan; 60(1):239-44. PubMed ID: 26482312
[TBL] [Abstract][Full Text] [Related]
2. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria.
Stryjewski ME; O'Riordan WD; Lau WK; Pien FD; Dunbar LM; Vallee M; Fowler VG; Chu VH; Spencer E; Barriere SL; Kitt MM; Cabell CH; Corey GR;
Clin Infect Dis; 2005 Jun; 40(11):1601-7. PubMed ID: 15889357
[TBL] [Abstract][Full Text] [Related]
3. Addition of teicoplanin or vancomycin for the treatment of documented bacteremia due to gram-positive cocci in neutropenic patients with hematological malignancies: microbiological, clinical and economic evaluation.
D'Antonio D; Staniscia T; Piccolomini R; Fioritoni G; Rotolo S; Parruti G; Di Bonaventura G; Manna A; Savini V; Fiorilli MP; Di Giovanni P; Francione A; Schioppa F; Romano F
Chemotherapy; 2004 Jun; 50(2):81-7. PubMed ID: 15211082
[TBL] [Abstract][Full Text] [Related]
4. Time Course and Extent of Renal Function Changes in Patients Receiving Treatment for Staphylococcal Pneumonias: An Analysis Comparing Telavancin and Vancomycin from the ATTAIN Trials.
Nogid B; Lacy MK; Jacobs M; Bruss J; Dwyer J
Pharmacotherapy; 2018 Oct; 38(10):990-998. PubMed ID: 30003567
[TBL] [Abstract][Full Text] [Related]
5. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study.
Stryjewski ME; Chu VH; O'Riordan WD; Warren BL; Dunbar LM; Young DM; Vallée M; Fowler VG; Morganroth J; Barriere SL; Kitt MM; Corey GR;
Antimicrob Agents Chemother; 2006 Mar; 50(3):862-7. PubMed ID: 16495243
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of daptomycin in the treatment of Gram-positive catheter-related bloodstream infections in cancer patients.
Chaftari AM; Hachem R; Mulanovich V; Chemaly RF; Adachi J; Jacobson K; Jiang Y; Raad I
Int J Antimicrob Agents; 2010 Aug; 36(2):182-6. PubMed ID: 20452752
[TBL] [Abstract][Full Text] [Related]
7. Telavancin hospital-acquired pneumonia trials: impact of Gram-negative infections and inadequate Gram-negative coverage on clinical efficacy and all-cause mortality.
Lacy MK; Stryjewski ME; Wang W; Hardin TC; Nogid B; Luke DR; Shorr AF; Corey GR; Barriere SL
Clin Infect Dis; 2015 Sep; 61 Suppl 2():S87-93. PubMed ID: 26316562
[TBL] [Abstract][Full Text] [Related]
8. Epidemiology and emerging resistance in bacterial bloodstream infections in patients with hematologic malignancies.
Kara Ö; Zarakolu P; Aşçioğlu S; Etgül S; Uz B; Büyükaşik Y; Akova M
Infect Dis (Lond); 2015; 47(10):686-93. PubMed ID: 26024284
[TBL] [Abstract][Full Text] [Related]
9. A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study.
Stryjewski ME; Lentnek A; O'Riordan W; Pullman J; Tambyah PA; Miró JM; Fowler VG; Barriere SL; Kitt MM; Corey GR
BMC Infect Dis; 2014 May; 14():289. PubMed ID: 24884578
[TBL] [Abstract][Full Text] [Related]
10. Effects of teicoplanin and those of vancomycin in initial empirical antibiotic regimen for febrile, neutropenic patients with hematologic malignancies. Gimema Infection Program.
Menichetti F; Martino P; Bucaneve G; Gentile G; D'Antonio D; Liso V; Ricci P; Nosari AM; Buelli M; Carotenuto M
Antimicrob Agents Chemother; 1994 Sep; 38(9):2041-6. PubMed ID: 7811016
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of telavancin compared with vancomycin and linezolid against Gram-positive organisms isolated from cancer patients.
Rolston K; Wang W; Nesher L; Coyle E; Shelburne S; Prince RA
J Antibiot (Tokyo); 2014 Jul; 67(7):505-9. PubMed ID: 24824818
[TBL] [Abstract][Full Text] [Related]
12. Telavancin: a novel lipoglycopeptide for serious gram-positive infections.
Laohavaleeson S; Kuti JL; Nicolau DP
Expert Opin Investig Drugs; 2007 Mar; 16(3):347-57. PubMed ID: 17302529
[TBL] [Abstract][Full Text] [Related]
13. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms.
Stryjewski ME; Graham DR; Wilson SE; O'Riordan W; Young D; Lentnek A; Ross DP; Fowler VG; Hopkins A; Friedland HD; Barriere SL; Kitt MM; Corey GR;
Clin Infect Dis; 2008 Jun; 46(11):1683-93. PubMed ID: 18444791
[TBL] [Abstract][Full Text] [Related]
14. Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children.
Kaplan SL; Deville JG; Yogev R; Morfin MR; Wu E; Adler S; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB;
Pediatr Infect Dis J; 2003 Aug; 22(8):677-86. PubMed ID: 12913766
[TBL] [Abstract][Full Text] [Related]
15. Changing aetiology, clinical features, antimicrobial resistance, and outcomes of bloodstream infection in neutropenic cancer patients.
Gudiol C; Bodro M; Simonetti A; Tubau F; González-Barca E; Cisnal M; Domingo-Domenech E; Jiménez L; Carratalà J
Clin Microbiol Infect; 2013 May; 19(5):474-9. PubMed ID: 22524597
[TBL] [Abstract][Full Text] [Related]
16. Activity of telavancin against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) in vitro and in an in vivo mouse model of bacteraemia.
Hegde SS; Skinner R; Lewis SR; Krause KM; Blais J; Benton BM
J Antimicrob Chemother; 2010 Apr; 65(4):725-8. PubMed ID: 20139142
[TBL] [Abstract][Full Text] [Related]
17. Bacteremia in febrile cancer patients in Uganda.
Lubwama M; Phipps W; Najjuka CF; Kajumbula H; Ddungu H; Kambugu JB; Bwanga F
BMC Res Notes; 2019 Jul; 12(1):464. PubMed ID: 31362783
[TBL] [Abstract][Full Text] [Related]
18. Telavancin Activity against gram-positive bacteria isolated from patients with skin and skin-structure infections.
Pfaller MA; Rhomberg PR; Sader HS; Mendes RE; Jones RN
J Chemother; 2010 Oct; 22(5):304-11. PubMed ID: 21123152
[TBL] [Abstract][Full Text] [Related]
19. ATLAS trials: efficacy and safety of telavancin compared with vancomycin for the treatment of skin infections.
Barriere SL
Future Microbiol; 2010 Dec; 5(12):1765-73. PubMed ID: 21080861
[TBL] [Abstract][Full Text] [Related]
20. Comparison of efficacy and safety of teicoplanin and vancomycin in children with antineoplastic therapy-associated febrile neutropenia and gram-positive bacteremia.
Sidi V; Roilides E; Bibashi E; Gompakis N; Tsakiri A; Koliouskas D
J Chemother; 2000 Aug; 12(4):326-31. PubMed ID: 10949982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
